CompletedPhase 2

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

United States18 participantsStarted 2024-08-15

Plain-language summary

This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subjects will have known gadolinium-enhancing CNS lesions and will have a gadolinium-based contrast agent-enhanced MRI of the brain 2-14 days before receiving RVP-001 with imaging. The ultimate goal of this research program is development of a gadolinium-free alternative to current general purpose MRI contrast agents.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults of all sexes, aged 18-75 years
✓. Patients with known enhancing CNS lesions, including but not limited to gliomas, meningiomas, glioblastomas, schwannomas, brain metastases, multiple sclerosis lesions, that are on an ongoing follow-up MRI schedule
✓. Patients who have had a GBCA-enhanced MRI within the past 14 days which demonstrated focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory disorders) including at least one enhancing lesion of minimum 5 mm (long axis)
✓. Acceptable renal function

Exclusion criteria

✕. Serious non-malignant disease that could compromise protocol objectives in the opinion of the investigator and/or the Sponsor
✕. Body mass index (BMI) greater than 35
✕. Patients with clinically significant cardiac disease
✕. MRI incompatibility

What they're measuring

Adverse Events

Timeframe: From time of dosing to 7 days post dose

Lesion visualization criteria for RVP-001 enhanced MRI compared to unenhanced MRI

Timeframe: 1 day

Lesion visualization criteria for RVP-001 compared to gadolinium-based contrast agent (GBCA)

Timeframe: 1 day

Trial details

NCT IDNCT06322342

SponsorReveal Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-12-19

View on ClinicalTrials.gov More Central Nervous System (CNS) Lesions trials